MTF1 and prostate adenocarcinoma: As for the primary therapy outcome, complete response (CR) patients had lower MTF1 expression than non-CR patients in BLCA, DLBC, and LGG, while in HNSC and prostate adenocarcinoma (PRAD), the results were reversed (Fig. 2C, Supplementary Fig. S1C).